Aquestive Therapeutics Inc.

06/11/2025 | Press release | Distributed by Public on 06/11/2025 15:22

Proxy Results (Form 8-K)

Item 5.07
Submission of Matters to a Vote of Security Holders
(a) Aquestive Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting") on June 11, 2025.
(b) The final voting on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.
(1) The following director nominees were elected to serve as Class I members of the Board of Directors, to serve for a three-year term until the Company's 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified:
Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes
Daniel Barber 36,060,882 - 3,546,668 29,848,112
Timothy E. Morris 35,562,599 - 4,044,951
(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.
Votes For Votes Against Votes Abstaining Broker Non-Votes
32,454,278 6,694,084 459,188 29,848,112
(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified.
Votes For Votes Against Votes Abstaining
66,530,646 1,166,766 1,758,250
Aquestive Therapeutics Inc. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 11, 2025 at 21:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io